Effects of Mitopure (Urolithin A) on Skeletal Muscle Function, Iron Metabolism and Endurance Performance
Launched by AMAZENTIS SA · Mar 3, 2021
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Age between 18-40 years
- • Participants will be running \>100 km/week
- • Elite participants will be required to have a 3,000 m running personal best time below 9:00 (mm:ss), and/or a VO2max result greater than 65 ml·kg-1·min-1
- • The sub-elite cohort will have a 3,000 m running personal best faster than 10:00 min and/or a VO2max \>60 ml·kg-1·min-1
- • Agree to participate in one of two \~4 week training camps been held between March-October 2021.
- • Signed informed consent
- Exclusion Criteria:
- • Subjects with diagnosed medical conditions involving thyroid function or other chronic disturbances of metabolic rate
- • Subjects who are unable to complete the training or testing protocols
About Amazentis Sa
Amazentis SA is a biotechnology company focused on advancing health through the development of innovative nutritional and therapeutic solutions. With a strong emphasis on scientific research and clinical validation, Amazentis leverages cutting-edge technologies to explore the potential of bioactive compounds in promoting metabolic health and enhancing overall well-being. The company is dedicated to transforming scientific discoveries into effective products that address pressing health challenges while maintaining a commitment to sustainability and evidence-based practices. Through strategic collaborations and rigorous clinical trials, Amazentis aims to contribute significantly to the fields of nutrition and health optimization.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Canberra, , Australia
Patients applied
Trial Officials
Louise Burke, OAM PhD
Principal Investigator
Australian Catholic University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials